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The title compounds are not available by hydrolysis of the pertinent esters on 
a preparative scale. Therefore, they were prepared by base catalyzed conden-
sation of dicarboxylic acid dichlorides or succinic acid monobenzylester-
chloride, respectively, with dithranol (1). Their ICso-values for glucose-6-
phosphate dehydrogenase are lower than that of dithranol (1), whilst 10-
ethyldithranol (6) and the o-(o>carboxyalkyl)-derivatives 8 and 9 are weaker 
inhibitors. 
10-(o>Carboxyacyl)-Derivate des Dithranols 
Die Titelverbindungen sind nicht aus den entspr. Estern präparativ zugäng-
lich, sondern wurden aus Dicarbonsäuredichloriden bzw. Bernsteinsäure-
monobenzylesterchlorid und Dithranol (1) hergestellt Die ICso-Werte dieser 
Substanzen für Glucose-6-phosphat-Dehydrogenase sind kleiner als der von 
Dithranol (1), 10-Ethyldithranol (6) und die o-(co-Carboxyalkyl)-Derivate 8 
und 9 sind dagegen schwächere Inhibitoren. 
10-Acyl-derivatives of dithranol (1) have been introduced as antipsoriatic 
agents by Mustakalliol\ butantrone (2b) being the most effective com-
pound of a series with 2 to 5 and with 14 C-atoms in the C-10 side chain2*. 
According to Krebs^ the C-10-acylated dithranol derivatives are consider-
ed to be pro-drugs on account of their phenylogous ß-dicarbonyl moiety. 
H O 0 
-R00R' 
and tautomers 
We have reported on the synthesis of 10-(Cu-methoxycar-
bonyl)-acyl-dithranol derivatives (type 3)4). One of these 
compounds has been described by Rychener et al. 5 ) as the 
ethoxy analogue in the meantime. Compounds 3 cannot be 
hydrolized to the corresponding 10-(o>-carboxyacyl)-deriva-
tives 4 on a preparative scale6). We tried LiBr/pyridine; 
BBr3/absol. CH2Cl2;ClSi(CH3)3/NaI/CH3CN and NaI/AlCl3/ 
CH3CN, but we obtained always dithranol (1) besides - in 
some cases - starting material 3. These findings are corrobo-
rated by efforts of Rychener et al.5 ) with compound 3a 
(ethoxy), who found a peak in the HPLC-chromatogram 
which they considered to be acid 4a, but they could neither 
isolate nor identify it. We have synthesized the carboxylic 
acid 4a not via the corresponding esters but by acylation of 
1 at C-10 making use of succinic acid monobenzylester-
chloride (yielding 10) with subsequent hydrogenolysis. For 
the synthesis of 4b and 4c we reacted the dichlorides of glu-
taric and adipic acid, respectively, with dithranol (1). With 
adipic acid dichloride we isolated the corresponding lactone 
5b as a side product. With succinylchloride only the lactone 
5a is formed4). The tic of the crude material formed from 1 
and glutarylchloride indicates traces of an analogous lactone 
which was not isolated. The retention time of acid 4a (t = 
4.55 min) under the HPLC experiment conditions reported 
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H O 0 O H 
by Rychener et al. 5 ) corroborate their assumption that the 
compound not isolated in their experiments (vide supra) is 
indeed 4a. 
Glucose-6-phosphate dehydrogenase (EC 1.1.1.49, from 
Baker's yeast, G-6-PDH) is highly increased in psoriatic 
tissues7). So a lot of publications are concerned with the 
interaction of (potential) antipsoriatics with this enzyme in 
vitro (e.g. Raab*\ Wiegrebe9\ Shrootl0)...). This kind of ex-
periments is important because psoriasis is not known in 
animals and, therefore, there are analogous1 l ) , l 2 ) but no strict 
animal models available to test new compounds. 
We tested 10-ethyl-dithranol (6)13), representing a C-10-
alkylated dithranol, l-hydroxy-9-anthrone (7)14), the 
minimal antipsoriatic structure according to Krebs and 
Schalteggerl5\ C-2-(co-carboxy-alkyl)-dithranol derivatives 
[8,9]4), C-10-acylated dithranol derivatives [2,3,4]16)4) and 
the lactones 5 without a "free" CH2-moiety. We want to 
emphasize that these lactones are effective by themselves: 
after 30 min of incubation (cf. Experimental Part) about 
75% of the lactone 5b were determined unchanged, about 
10% of chrysazin (la) have arisen, but no significant quan-
tity of the corresponding acid 4c was detected by HPLC. 
The IC5o-values of the compounds listed in table 1 were 
determined by graphic means from at least 7 points (fig. 1). 
For each concentration the mean value of three 
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Fig.2: HPLC-separations 
Table 1: ICso-values of all tested compounds 
compound ICso-value 
8 6.610" 4 M 
9 3.810" 5 M 
6 2.2-l(r 5 M 
9b 1.810~ 5M 
7 9.410" 6 M 
3b 9.2 1(T 6 M 
1 8.01(T 6 M 
3a 6.4-10" 6M 
2a 5.010" 6 M 
5a 1.7 10" 6 M 
5b 1.71(T 6 M 
2b 1.3-10"6M 
4c 9.010" 7 M 
4a 2.8-10' 7 M 
4b 2 .210" 7 M 
% I n h i b i t i o n 
F i g . l : Inhibition of Glucose-6-phosphate Dehydrogenase; IC50 values of selected compounds 
determinations was used. The inhibition rate is shown as % 
of the control (cf. Experimental Part). 
According to Rychener et al. 5 ) dithranol (1) is a more 
potent inhibitor than his ester 3a (ethyl instead of methyl). 
In our experiments the IC50-values of 3a and 3b are of 
similar magnitude as that of 1 (table 1). On the other hand 
the free acids 4a-c are far stronger inhibitors than dithranol. 
This holds true also for the lactones 5a,b and for butantrone 
2b, so making Krebs' hypothesis of a pro-drug character3* 
of C-10-acylated dithranol derivatives disputable. More-
over, our HPLC experiments of the incubation tests indicate 
that there is neither dithranol (1), nor its degradation 
product lb to be seen after 30 min of incubation of all the 
C-10-acylated dithranol derivatives tested (fig. 2a)). Dithra-
nol (1), however, is degraded nearly perfectly, bianthron 
(lb, about 60%) and chrysazin (la, about 20%) were found 
as degradation products (fig. 2b)). The mechanism for the 
formation of minor amounts of chrysazin (la) from the 
lactone 5b and the acid 4b (fig.2) is unknown. 
These experiments indicate that compounds 3, 4, and 5 are 
effective by themselves in this test. If dithranol (1) formed 
by hydrolysis of 3-5, respectively, were the active principle, 
the efficacy of the lactones 5 and acids 4 should not exceed 
that of 1. 
Experimental Part 
Devices: Mp.: (uncorr.) apparatus according to Dr. Tottoli (Büchi).- U V -
spectra: Shimadzu 210; 1 cm cells.- IR-spectra in K B r : Beckman Acculab 
III.- ^-NMR-spectra : Varian E M 390, CDC1 3 , 35°C, T M S as int. stand.-
M S : Varian M A T CH5, 70 eV.- N I - F A B - M S (glycerol/DMSO 1:1; Xe) 
Varian M A T 311 A . - H P L C : pump: Kontron 420; UV-detector: Kontron 
Uvikon 735 L C ; integrator: Merck-Hitachi D-2000; injection system: 
Rheodyn.- A l l the reactions were performed under N 2 and light protection. 
I, 8-Dihydroxy-10-(3' -benzyloxycarbonyl-1' -oxopropyl)-9(l OHjanthra-
cenone (10) 
The suspension of 2.26 g 1 (10 mmol) and 3.0 g (13.25 mmol) succinic 
acid benzylester-chloride1 7 ) in 80 ml of absol. toluene and 1.0 g (13 mmol) 
of dry pyridine is refluxed for 6 h. The resulting orange solution is evapora-
ted i.vac, the residue, dissolved in a small volume of CH 2 Cl2 , is separated 
from 1 (1 g, 44%) by C C (Si02/CH 2C1 2): 1.4 g 10 (60%, related to reacted 
1), yellow crystals, m.p. 125°C- C 2 5 H 2 0 O 6 (416.4).- Gälc. C 72.1 H 4.84 
Found C 71.9 H 4.80.- U V (MeOH): X max (log e) = 359 (4.02), 279 
(3.97), 261 (4.18), 208 nm (4.44).- IR: 1750 (COOR); 1720 ( G O ) ; 1640; 
1615; 1605 cm"1 ( O O - H O ) . - ^ - N M R : 8 (ppm)= 12.20 (s; 2H, OH), 
7.60-6.83 (m; 11H aromat.), 5.22 (s; 1H at C-10), 5.0 (s; 2H; -0-CH 2 -Ph) , 
2.39 (s; 4H; - C H 2 - C H 2 - ) . 
4-( 1,8-Dihydroxy-9(10H)-anthracenon-10-yl)-4-oxo-butyric acid (4a) 
600 mg 10 are dissolved in 30 ml of absol. THF. After addition of 70 mg 
Pd-C (5% Pd) the solution is stirred until the theoretical amount of H 2 has 
been absorbed (24 h, tic-control). Having sucked off the catalyst the solu-
tion is evaporated i.vac. Recrystallisation from M e O H / H 2 0 leads to 350 
mg (75%) 4a, yellow crystals, m.p. 165°C- C 1 8 H 1 4 0 6 (326.3).- Calc. C 
66.3 H 4.32 Found C 66.3 H 4.63.- U V (MeOH): X max (log e) = 357 
(3.96), 285 (3.88), 257 (3.94), 203 nm (4.37).- IR: 3060-2600 (COOH); 
1720 (C=0); 1640; 1615; 1605 cm"1 (C=0 -HO). - ^ - N M R : 8 (ppm) = 
I I . 98 (s; 2H, OH), 7.75-6.98 (m; 6H aromat.), 5.70 (s; 1H at C-10), 2.90 (t; 
J = 7Hz; 2H; C H 2 at C-2), 2.31 (t; J = 7Hz; 2H, C H 2 at C-3).- N I - F A B - M S : 
m/z = 325 [(M-H)"; 3.4%], 225 [(M-H)" - C 4 H 5 0 3 ; 100%].- P I - F A B - M S : 
m/z = 327 ( M H + ; 54%), 227 ( M H + - C4H5O3; 100%). 
5- (l ,8'Dihydroxy-9(10H)-anthracenon-10-yl)-5-oxo-pentylic acid (4b) 
2.26 g 1 (10 mmol) and 4.0 g (23.7 mmol) glutarylchloride 1 8 ) are suspen-
ded in 70 ml of absol. toluene and 1.0 g (13 mmol) of dry pyridine. The su-
spension is refluxed for 2 h (tic-control). The resulting solution is 
evaporated i.vac. The residue is dissolved in ether and shaken with satura-
ted NaHC0 3-solution changing the colour of the alkaline solution to red. 
Acidifying the aqueous layer with acetic acid yields a yellow coloured so-
lution which is extracted with ether. The combined ether layers are dried 
over N a 2 S 0 4 and evaporated i.vac. Recrystallisation from M e O H / H 2 0 
leads to 2.21 g (65%) 4b, yellow crystals, m.p. 125°C- C i 9 H 1 6 0 6 (340.3).-
Calc. C 67.1 H 4.74 Found C 66.9 H 4.74.- U V (MeOH): X max (log e) = 
357 (3.99), 281 (3.99), 260 (4.07 ), 215 nm (4.20).- IR: 3040-2600 
(COOH); 1720 (C=0); 1705 (COOH); 1635; 1615; 1605 cm" 1 
(C=0- -HO).- ! H - N M R ( [ D 6 ] D M S O / C D C l 3 1:1): 8 (ppm) = 12.0 (s; 2H; 
OH), 7.68-6.9 (m; 6H aromat), 5.4 (s; 1H at C-10), 2.4 (t; J = 7Hz; 2H; 
C H 2 at C-2), 2.0 (t; J = 7Hz; C H 2 at C-4), 1.58 (quint.; J = 7Hz; C H 2 at C-
3).- N I - F A B - M S : m/z = 339 [(M-H)"; 58%], 225 [(M-H)" - C 5 H 7 0 3 ; 
100%].- P I - F A B - M S : m/z = 341 ( M H + ; 36%), 227 ( M H + - C 5 H 7 0 3 ; 
100%). 
6- (l ,8-Dihydroxy-9(10H)-anthracenon-10-yl)-6-oxo-hexylic acid (4c) 
4c is prepared analogously to 4b from 2.26 g 1 (10 mmol) and 2.77 g (15 
mmol) adipic acid dichloride 1 9 ): 360 mg (30%), yellow crystals, m.p. 
128°C- C 2 0 H 1 8 O 6 (354.4).- Calc. 67.8 H 5.12 Found C 67.8 H 5.18.- U V 
(MeOH): X max (log e) = 358 (3.99), 260 (4.18), 209 nm (4.31).- IR: 3420 
(OH); 3040-2800 (COOH); 1720 (C=0); 1705 (COOH); 1640; 1620; 1610 
cm" 1.- ! H - N M R : 8 (ppm) = 12.15 (s; 2H, O H , br.), 10.5-9.1 (s; 1H; C O O H , 
br.), 7.6-6.78 (m; 6 H aromat.), 5.19 (s; 1H at C-10), 2.18-1.7 (m; 4H; C H 2 
at C-2 and at C-5), 1.45-1.12 (m; 4H; C H 2 at C-3 and at C-4).- N I - F A B -
M S : m/z = 353 [(M-H)"; 14%], 225 [(M-H)" - C 6 H 9 0 3 ; 100%].- P I -FAB-
M S : m/z = 355 ( M H + ; 21%), 227 ( M H + - C 6 H 9 0 3 ; 100%). 
1,8-Dihydroxy-10-(7' -oxepanyliden-2' -on)-9(10H)-anthracenone (5b) 
Working up the ether layer of 4c by C C ( S K t y C H ^ y yields 510 mg 1 
(23%) and the lactone 5b: 60 mg (1.8%), yellow crystals, m.p. 188-190°C-
C2oHi 60 5 (336.3).- Calc. C 71.4 H 4.79 Found C 71.4 H 4.83.- U V 
(MeOH): X max (log e) = 383 (4.12), 299 (4.01), 228 (4.54), 205 nm 
(4.38).- IR: 1765 (£-lactone); 1630; 1605 cm" 1 (C=0 -HO).- ! H - N M R : 8 
(ppm) = 12.11 (s; 1H; OH), 12.05 (s; 1H; OH), 7.6-6.9 (m; 6 H aromat.), 
2.92-2.51 (m; 4H; C H 2 at C-2 ' and at C-5'), 2.18-1.82 (m; 4H; C H 2 at C-3* 
and at C-4').- M S : m/z = 336 (M+-, 100%), 318 ( M + - - H 2 0 ; 62), 290 (72), 
252 ( M + - - (CH 2 ) 4 CO; 84), 226 (100), 224 (67). 
Inhibition of G-6-PDH 
Solutions: For all the solutions bidistilled water is used. G-6-P-solution: 
130 mg G+6-P-di-Na (Sigma) are dissolved in 10 ml water.- NADP + - so lu-
tion: 100 mg ß-NADP + -mono-Na (Sigma) are dissolved in 5 ml of 1% 
NaHC0 3-solution.- Buffer: Ringer solution: 8.0 g NaCl , 0.2 g K C l , 1.0 g 
N a H C 0 3 , 0.2 g C a C l 2 and 0.1 g M g C l 2 are dissolved in 900 ml of water. 
P H is adjusted to pH 7.5 with H C l and water is added to 1000.0 ml.-
Enzyme-dilution: G-6-PDH (Sigma, type VII, from Baker's yeast) is used 
in a dilution of 1:1000 with buffer.- Test-solution: The concentration of the 
stock solution is about 4 1 0 " 3 M (1 mg/ml of substance to be tested, dissol-
ved in acetone, p.a. Merck). Addition of 20 ul of the stock solution to the 
incubation volume leads to a concentration of 1.75-10"5M in this solution (5 
ml). The variety of concentrations is prepared by diluting different amounts 
of stock solution with acetone. Incubation preparation (5 ml): For each 
value 4.48 ml buffer, 0.5 ml enzyme dilution and 20 |xl test-solution of the 
required concentration are shaken in a water bath for 30 min at 37°C under 
light protection. The corresponding control value (buffer - enzyme dilution 
- acetone), measured analogously, is determined every h because the activi-
ty of the enzyme decreases steadily. A l l solutions are freshly prepared just 
before measurement. For each concentration three determinations are 
made. 
Determination: wavelength 340 nm, temp. 25°C, volume 3.0 ml, 1 cm cu-
vettes. 
buffer 2.40 ml 
incubation volume 0.50 ml 
NADP + -solution 0.05 ml 
mix 
G-6-P-solution 0.05 ml 
After mixing the extinction is measured every min during 5 min. The in-
hibition is expressed in % of the control. 
HPLC-conditions 
Column: Nucleosil 100, R P 18, 7 \im, 280 x 4 mm Kontron.- mobile 
phase: MeOH/H 2 0/acetic acid (85:15:0.1).- flow: 1 ml/min.- pressure: 106 
bar.- detection: 254 nm.- injection volume: 20 uX 
Determination of the retention time of each substance: about 1- 10" 5M so-
lutions in methanol are prepared and 20 \i\ are injected. 
Retention time (min): 4a (4.55), 4b (4.75), 4c (5.25), 3a (5.87), 3b (6.4), 
5b (8.24), 2b (8.84), la (9.44), 1 (10.21), lb (15.2). 
In order to scrutinize the stability of these substances during 30 min of 
incubation (pH 7.5, water bath, light protection, 37°C), we examined these 
preparations by H P L C ; especially we looked for dithranol (1): after 30 min 
the incubation volume (5 ml) is diluted with 10 ml of water and purified by 
a Baker-column (C-18, 10 SPE™). Elution of the substance with 3 ml 
M e O H ; HPLC-injection. The recovery rate was determined for 3a and 4b 
and found to be 90 and 105%, respectively. 
Results of HPLC 
After 30 min of incubation 70-85% of the substances 2, 3, 4, and 5 are 
found; dithranol (1) was never detected, but there are small amounts of 
chrysazin (la, 5-20%). Dithranol (1) is not stable during this incubation 
(vide supra). 
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